TIDES USA: Oligonucleotide and Peptide Therapeutics 2023
Access novel science across the entire oligonucleotide, peptide, and mRNA spectrum
Each year, TIDES’ scientific agenda includes 150+ of the industry’s top scientists to present the latest science and industry updates across the entire spectrum from discovery, preclinical, clinical development through CMC, Manufacturing and commercialization of therapeutics and vaccines for oligos, peptides, mRNA and genome editing products.
TIDES USA is the flagship must-attend event in the TIDES: Oligonucleotide & Peptide Therapeutics portfolio. It is the world’s largest gathering for those interested in accelerating oligonucleotide, peptide, mRNA and genome editing products from early discovery to late-stage development and commercialization.
CONFIRMED KEYNOTES FOR TIDES 2023
Each year, the TIDES conference scientific agenda includes 150+ of the industry’s top scientists to present the latest science and industry updates across the entire spectrum from discovery, preclinical, clinical development through CMC, Manufacturing and commercialization of therapeutics and vaccines for oligos, peptides, mRNA and genome editing products.
Eliana Clark, PhD
Executive Vice President and Chief Technical Officer
Intellia Therapeutics
Marcus Schindler, PhD
Executive Vice President for Research & Early Development and CSO
Novo Nordisk A/S
Sekar Kathiresan, MD
Co-Founder, CEO and Board Member
Verve Therapeutics
Alanna Schepartz, PhD
Professor of Chemistry
UC Berkeley
Lukas Scheibler, PhD
Chief Innovation Officer
Apellis
Click the link to see all the confirmed sponsors & speakers for the 2023 TIDES USA Hybrid Event.
The TIDES USA program features concurrent tracks covering the following 6 scientific themes including in-depth development strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing. Your registration provides access to the presentations across all 4 tracks, allowing you to create your own customized agenda.
Oligonucleotide Chemistry, Manufacturing & Controls
Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.
Oligonucleotide Discovery, Preclinical and Clinical
Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.
Peptide Chemistry, Manufacturing & Controls
Improve process efficiencies and overcome challenges in process development, CMC and manufacturing. Understand regulatory expectations, new technologies and alternative approaches for emerging complex molecules.
Peptide Discovery, Preclinical and Clinical
Explore new frontiers in peptide synthesis, discovery, design and engineering to improve targeting, delivery and drug-like properties. Case studies on the latest preclinical and clinical successes of peptides and peptide-like scaffolds and structures.
mRNA Therapeutics/Vaccines & Genome Editing
Hear updates on discovery strategies, clinical progress and CMC approaches for mRNA therapeutics and vaccines from industry-leading companies, and learn about state-of-the-art technologies for genome editing applications and hear about progress in genome editing delivery
Drug Delivery Innovations
Explore new technologies and approaches in the delivery of macromolecular therapeutics featuring multiple case studies of the delivery of oligonucleotides, peptides, mRNA therapeutics and genome editing delivery strategies. Learn about cutting-edge delivery advances including targeted delivery approaches for oligonucleotides, device-based delivery strategies and oral delivery of peptides.